Acetylsalicylic acid improves outcome after acute myocardial infarction by reducing thromboinflammation.
Carolin Helten, Marcel Benkhoff, Philipp Mourikis...
https://pubmed.ncbi.nlm.nih.gov/41791655Actively Recruiting
Age: 18Years +
All Genders
ID03539133
Systemic Organ Communication in STEMI
Led by Heinrich-Heine University, Duesseldorf · Updated on 2026-01-22
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting an observational study to understand systemic organ communication in patients with ST-segment elevation myocardial infarction (STEMI). Despite advances in emergency care and treatment, STEMI remains a serious condition with significant health risks. This study aims to gather clinical data prospectively and systematically from STEMI patients to identify key factors influencing myocardial ischemia. Participants are observed without intervention, with ongoing collection of their clinical data. This open-ended cohort study tracks various cardiac functions and outcomes over time. The focus is on understanding heart function and changes after STEMI, without assigning any specific treatments or therapies. During the study, participants' heart function and structure will be evaluated at multiple points, including during hospitalization and up to six months afterward. Researchers will monitor outcomes such as left-ventricular function, remodeling, myocardial texture, and vessel patency. Longer-term follow-up includes tracking mortality and hospital readmissions up to 12 months. Participant involvement includes clinical assessments and data collection without additional treatments.
CONDITIONS
Brief Title
Systemic Organ Communication in STEMI
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients suffering from STEMI
- 18 years of age or older
You will not qualify if you...
- Under 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 5 days
Participants undergo clinical data collection and imaging assessments during hospitalization.
1 to 2 visits during hospitalization
Long-term Monitoring
Duration - Up to 12 months
Participants are monitored to assess heart function and health outcomes over time.
Follow-up visits at 6 and 12 months
Trial Site Locations
Total: 1 location
1
Division of Cardiology, Pulmonary Disease and Vascular Medicine
Düsseldorf, Germany, 40225
Actively Recruiting
Loading map...
Research Team
C
Christian Jung, MD, PhD
F
Florian Bönner, MD,
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Thromboinflammation is associated with clinical outcome after ST-elevation myocardial infarction.
Marcel Benkhoff, Karin Alde, Vincent Ehreiser...
https://pubmed.ncbi.nlm.nih.gov/39226457SYSTEMI - systemic organ communication in STEMI: design and rationale of a cohort study of patients with ST-segment elevation myocardial infarction.
Florian Bönner, Christian Jung, Amin Polzin...
https://pubmed.ncbi.nlm.nih.gov/37138228